In a meeting held on December 20, 2024, the Fund Raising Committee of the company had approved the issue of 1.19 crore equity ...

Mumbai: The National Green Tribunal (NGT) has dismissed allegations of water pollution against the Ambernath plant of Bharat ...

Advent International has been present in India since 2007 and has committed over $6 billion in that time, spread across 19 ...

Mankind Pharma, India’s fourth-largest pharmaceutical company by domestic sales, has officially launched its Rs 3,000 crore ...

The pharma company has acquired 100% stake in BSV for ₹13,768 crore, to be funded through a combination of internal accruals ...

Mankind Pharma has launched a Rs 3,000 crore QIP to fund its acquisition of Bharat Serums and Vaccines. The company has seen ...

The QIP opened on December 16, 2024, with Mankind Pharma keeping the option to offer a discount of up to 5% on the floor ...

The indicative issue price for the QIP is expected to be approximately ₹2,520 per share, which could lead to an equity ...

The proposed capital raise is part of Mankind Pharma's plan to fund the Rs 13,630-crore acquisition of private equity firm ...

The department offers flu, COVID-19, Tdap and RSV vaccines to adults and children for little to no cost this season. Flu and COVID-19 cases traditionally peak in the winter. Since the week of Nov ...

Bharat Serums and Vaccines Limited (BSV) told Financial Express.com. BSV is one of key anti-snake venom manufacturers in India and it offers a wide range of anti-venom products for snake bites and ...

Kevevapi, established on March 5, 1990, has the expertise and facilities to produce 15 livestock vaccines. Wamuchomba said the move could potentially affect animals' productivity and reproductivity.